| Studientitel | Status | Seit | Medikation |
| Incyte - A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
|
Aktiv
|
17.01.2018
|
Tyrosine Kinase Inhibitor INCB054828
|
| POTOMAC: Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients
|
Aktiv
|
|
Durvalumab and BCG vs BCG alone
|
| WO29636 - A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION
|
Aktiv
|
Rekrutierung abgeschlossen
|
Atezolizumab vs. Observation
|
| Seattle SNG22E-001A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy
|
In Planung
|
|
enfortumab vedotin (ASG-22CE)
|
| NKTR-214 Eine randomisierte, nicht vergleichende, unverblindete Studie der Phase 2 zu NKTR-214 in Kombination mit Nivolumab und zu Chemotherapie bei Patienten mit lokal fortgeschrittenem oder metastasierendem Urothelkarzinom mit niedriger PD-L1-Expression, die für eine Cisplatin-Therapie nicht geeignet sind
|
In Planung
|
|
Kombination mit Nivolumab und zu Chemotherapie
|
| 7465-CL-0301 An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
|
In Planung
|
|
Enfortumab Vedotin vs Chemotherapy
|
| MK-3475-866 / KEYNOTE 866 Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy in Cisplatin Eligible Patients with Muscle-Invasive Bladder Cancer
|
In Planung
|
|
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy
|
| Ansprechpartner |
|
|
|
|
OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: Tel.: 030-450 615092, Fax: 030-450 7515927
|
|
|
|
